

2023 Partners in Excellence – Concomitant GLP-1/DPP4 Use Program


Executive Overview, Targets, and Methodology

Overview

The Partners in Excellence program forms the basis for HealthPartners' financial and public recognition for pharmacy practices providing exceptional clinical quality and affordable care.

Our goal is to recognize and reward Pharmacy practices that deliver on the Triple Aim: To improve health while improving the affordability and consumer experience of health care.

Financial rewards are based on pharmacy practice performance as measured by HealthPartners technical specifications.



2023 – Quality Dimension: *Affordability*

For the 2023 Partners in Excellence program, HealthPartners is offering an additional Pharmacy practice opportunity focused on our Members who are utilizing dipeptidyl peptidase-4 inhibitors (DPP4) and glucagon like peptide 1 receptor agonists (GLP1) concomitantly.

The following principles are used in the Partners in Excellence program:

- Use measures that are relevant and clear to pharmacy practices and consumers
- Use measures that are accurate, valid, reliable and obtainable
- Use established measures, those endorsed nationally or generally accepted national or regional standards
- Draw on a range of measures from a variety of sources, where possible, for a robust overall rating methodology
- Apply consistent measurement approaches and use scoring that avoids or minimizes subjectivity
- Disclose the methodology so it is transparent to pharmacy practices, consumers and employers

Quality Performance Evaluation Steps

Quality Dimension: Affordability

Pharmacy Affordability Dimension Measure
Discontinuation of Concomitant DPP4-GLP1 Therapy



Quality Performance

Bonus pool payout determined by:
Number of members deemed to have discontinued either their DPP4 or GLP1 inhibitor x \$500

Pharmacy Measure

AFFORDABILITY

Discontinuation of Concomitant DPP4-GLP1 Therapy¹

Measure Source:

- 1 Internal HealthPartners measure

AWARD CALCULATIONS

Bonus payments are made bi-annually (for the periods November-April and May-October) based upon the number of successful discontinuations of either GLP1 or DPP4 therapy. Pharmacy practices will receive \$500 for each successful discontinuation of therapy.

APPENDIX I: Detailed Methodology

Program Eligibility

To be eligible for program inclusion in 2023, Pharmacy Practices must have at least 1 member identified by HealthPartners as receiving concomitant DPP4 and GLP1 therapy.

Measure Definitions

Discontinuation of Concomitant DPP4-GLP1 Therapy:

Members are deemed to be utilizing concomitant DPP4-GLP1 therapy if they have an overlapping days supply of a DPP4 and GLP1 medication on at least 2 separate occasions over a rolling 7-month period.

Members are deemed to have discontinued concomitant DPP4-GLP1 therapy when prescription claims data indicate more than 30 days have elapsed since days supply was exhausted for either a DPP4 or GLP1 medication and no additional prescription fill has occurred.

NOTES:

- Members are excluded from the bonus payment if pharmacy benefits and/or membership are terminated before the measurement period ends.

APPENDIX II: Frequently Asked Questions

What data will be communicated with me?

- Lists of members utilizing your care system or pharmacy who are concomitantly utilizing DPP4-GLP1s will be provided to you as opportunities are identified
- *Results will be available following each 6 month time period*

Which winners will be recognized at the Partners in Excellence Awards Ceremony?

Pharmacy practices will not be recognized at the Partners in Excellence Awards Ceremony

Whom do I call if I have more questions?

Please contact Nancy Jorgenson, Pharmacy Network Liaison, at 952-883-6838 or Nancy.J.Jorgenson@HealthPartners.com with any questions.